enGene Therapeutics Inc. (ENGN) stock
Close on Nov 12, 2026Market cap $152.80MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $152.80M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.66
- Dividend yield
- 0.00%
- Free cash flow yield
- -68.06%
Fundamentals
- Net income
- -$130.36M
- EPS, diluted
- $2.29
- Free cash flow
- -$104.00M
- Book value per share
- $3.30
- Diluted shares
- 70M
Trading
- Next earnings
- Dec 21, 2026 (estimated, during market hours)
- Previous close
- $1.80
- Open
- $1.93
- Day's range
- $1.90 – $2.35
- Volume
- 11,909,680
- Average volume (20 days)
- 1,532,640
- Beta (5 years)
- -0.50
- 52-week range
- $1.40 – $12.25
- RSI (14 days)
- 56.7
- Volatility (1 year)
- 118.2%
- Relative volume
- 3.46×
- WACC
- 7.8%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENGN | S&P 500 | Difference | ENGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +34.1% | -2.7% | +36.8 pts | ||
| 3 months | +34.1% | -1.7% | +35.9 pts | ||
| Year to date | -74.8% | +11.9% | −86.6 pts | ||
| 1 year | -73.7% | +12.0% | −85.7 pts | ||
| 3 years | -72.9% | +78.2% | −151.0 pts | -35.3% | +21.2% |
| 5 years | -95.3% | +73.2% | −168.6 pts | -45.8% | +11.6% |
| 10 years | -95.3% | +309.6% | −405.0 pts | -26.4% | +15.1% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases enGene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Update
About enGene Therapeutics
Biological Products, (No Diagnostic Substances)
enGene Holdings Inc. is a clinical-stage biotechnology company developing targeted genetic medicines delivered to mucosal tissues. Utilizing its proprietary DDX non-viral gene delivery platform, the company focuses on creating therapies for localized, high-unmet-need diseases. Its primary product candidate is detalimogene voraplasmid, an investigational treatment being evaluated in clinical trials for non-muscle invasive bladder cancer, specifically targeting patients with Bacillus Calmette-Guérin-unresponsive disease. The organization manages its research and development operations as a single business segment directed at treating bladder cancer patients.
Company profile, executives and historyenGene Therapeutics stock: common questions
What is enGene Therapeutics's stock price?
ENGN closed at $2.28 on Nov 12, 2026, up 26.67% on the day. Over the past 52 weeks it traded between $1.40 and $12.25.
What is enGene Therapeutics's market cap?
enGene Therapeutics was worth $152.80M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does enGene Therapeutics pay a dividend?
No. enGene Therapeutics has not paid a cash dividend over the last twelve months.
When does enGene Therapeutics report earnings next?
enGene Therapeutics is expected to report Q4 FY2026 results on Dec 21, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ENGN stock performed over the past year?
Including dividends, ENGN returned -73.7% over the past year, against +12.0% for the S&P 500.
Who are enGene Therapeutics's competitors?
Companies most similar to enGene Therapeutics by business, industry and size include SAEN, CGON, CLDI, CADL, CRDF.
See a number that looks wrong?